BioWorld

March 8, 2005

View Archived Issues

CTI Tumbles 47 Percent On Missed Endpoint For Xyotax

Cell Therapeutics Inc. lost almost half of its value Monday, following news that Xyotax missed the primary endpoint in its Stellar 3 pivotal trial in non-small-cell lung cancer patients. (BioWorld Today) Read More

Celgene's Revlimid Phase III Data Beat Specified Endpoint

Read More

To Better Characterize Iressa, Biomarker Studies Under Way

Read More

Sirtris' Series B Gets $27M For Class III HDAC Research

Read More

Other News To Note

Read More